The Company’s main strengths are: (i) a very new product portfolio, following the launch of six new products in the last two years; (ii) a benchmark product, Bemiparin, with good sales prospects, both in Spain and elsewhere; (iii) a contract manufacturing business with high value-added; and (iv) a sound, low-risk R&D division, with projects in very advanced phases that will be the Company’s future growth engine.